The addition of the new protease inhibitors (PIs) to peg-interferon (IFN) and ribavirin (RBV), approved for chronic hepatitis C, has clearly improved sustained virological response (SVR) rates although several adverse events have been reported with this regimens, including mild hematological toxicity.
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Abstract
The addition of the new protease inhibitors (PIs) to peg-interferon (IFN) and ribavirin (RBV), approved for chronic hepatitis C, has clearly improved sustained virological response (SVR) rates although several adverse events have been reported with this regimens, including mild hematological toxicity.
Moreover, severe pancytopenia and aplastic anemia during triple therapy with telaprevir has recently been described in seven patients. We report here two cases of severe agranulocytosis/aplastic anemia using boceprevir or simeprevir in interferon-based combination and 2 additional cases of severe myelosupression in IFN-free therapy with sofosbuvir and simeprevir plus RBV.
Our observations suggest that PIs could have a sort of class-effect in developing severe hematologic toxicity or, at least, an additive interaction with 3 3 other potentially myelotoxic agents such as IFN or RBV that are used in the classical regimens against HCV. Unfortunately, the mechanisms behind this phenomenon are currently unknown. In conclusion, given the life-threatening character of these complications, close monitoring is mandatory in patients under PIs based therapy to promptly detect serious hematological toxicities and to carefully evaluate treatment discontinuation. Prospective studies assessing the usefulness of RBV in the era of new IFN-free combinations are needed.
Introduction:
Protease inhibitors (PIs) have improved sustained virological response (SVR) in patients with chronic hepatitis C virus (HCV) when used in combination with peg-interferon and ribavirin (PR) [1] . Hematological adverse events with PR, like interferon (IFN)-related central myelosuppression or ribavirin (RBV)-related hemolytic anemia are usually mild [2] . Few cases of hematological serious adverse events (SAEs) in HCV infected patients receiving antiviral treatment with PR have been reported in the literature: two cases of severe aplastic anemia related to IFN-alfa and two cases of pure red cell anemia (PRCA) associated with peg-IFN and RBV, respectively [3, 4] .
Addition of the new PIs to PR has shown a high frequency of mild hematological toxicity [5, 6] . Our group has recently described severe pancytopenia or aplastic anemia in seven patients during triple therapy with telaprevir (TVR) [7] . Of note, these hematological complications resulted in a high mortality rate (three out of seven patients died). Interestingly, only one of these seven patients had both risk factors (low levels of platelet < 100 x 10 9 /L and albumin < 35 g/L) for developing adverse events, previously described in cirrhotic patients of the 4 4 CUPIC cohort [8] .
We here report two cases of severe agranulocytosis/aplastic anemia using including bacterial infections and clinical decompensation of liver disease [9] . In addition, severe pancytopenia and aplastic anemia during triple therapy, including TVR, have been recently reported [7] . This severe toxicity has shown a high risk of mortality, being imperative the close monitoring of these patients.
Recently, second generation PIs (SMV) have shown a better safety profile and lower risk of developing severe anemia than TVR, a first generation PI [10] .
IFN, in addition to its well-known antiviral effect, exerts antiproliferative activity on many cell types, including hematopoietic cells [4] . This property may lead to cytopenias that can interfere with the successful clinical application of IFN.
In contrast, RBV is a cytotoxic agent and its accumulation in erythrocytes produces oxidative membrane damage, leading to an accelerated extravascular hemolysis by the reticulo-endothelial system [11] . At a low dose, it decreases half-life of red cells with a reversible effect when the drug is discontinued, and at high doses, RBV also inhibits the release of red cells from the bone marrow [12] .
However, only few cases of severe hematologic toxicity induced by IFN/RBV therapy have been reported in HCV patients after many years of use in the daily practice [13, 14] .
We here report 4 cases of severe hematological toxicity in HCV patients receiving first or second generation PIs with or without IFN, but always with It is known that genetic variants leading to inosine triphosphatase (ITPA) deficiency protect against hemolytic anemia in HCV-infected patients receiving RBV [15] , but the mechanism sustaining severe anemia during PIs based therapy is still unknown. Recent reports investigating the molecular mechanisms of
anemia in anti-HCV triple therapy have shown that TVR-S isomer concentration is related to the concentration of RBV in plasma [16] . It is supposed that TVR can produce a boosting effect on plasma RBV and its intra-erythrocytic concentration, finally leading to a toxic effect. So that, it has been suggested a bimodal pattern: an early phase mainly due to acquired spherocytic-like hemolytic anemia and a late phase showing hyporegenerative features, most likely related to the combined effects of PR and PIs on erythropoiesis [17] .
In addition, we have also reported two additional patients who developed severe anemia and one of them also grade 4 neutropenia under IFN-free regimens (SMV and SOF plus RBV). Although this last patient had received rituximab for lymphoma treatment, at the time of starting HCV treatment he was in complete remission of the lymphoma and no clinical or laboratory findings due to cryoglobulinemia were evident. In addition, the coexistence of anemia and neutropenia is not consistent with the clinical picture seen in cases with delayed neutropenia induced by rituximab. To our knowledge, these are the first reported cases of severe hematologic toxicity associated to this three-agent regimen. One patient developed PRCA after 4 weeks of treatment, and the other initiated severe bicytopenia at 6 weeks of starting therapy. RBV was held in both patients, but SMV and SOF were maintained in one, and SMV was changed to DCV in the other. Although both patients required red blood cell transfusions and EPO, anemia rapidly improved in the following weeks.
This prompt recovery of anemia after RBV withdrawal in our patients suggests that RBV probably is the main causative agent of anemia in IFN-free regimens.
However, given the low incidence of PRCA due to RBV in the literature and the resolution of anemia after changing SMV for DCV in our case 4, we cannot completely rule out a possible additive toxic effect of SMV. Considering the high antiviral activity of SMV and SOF, we suggest that RBV might be avoided with these new regimens, especially in those patients with advanced liver disease and in those with mild cytopenias previous starting HCV treatment [18] . However, further studies are needed to evaluate the role of RBV in these new IFN-free regimens.
These cases of severe and life-threatening adverse events have occurred in our center in a period of scarcely 2 years in which about 170 patients received treatment with PIs. This observation highlights an unexpected high incidence of hematologic toxicity, something not previously observed by our group despite decades of treatment with PR. Moreover, these hematologic complications entail large amounts of health resources, including the use of support treatment with G-CSF and EPO, transfusions, broad spectrum antibiotics, antifungals and even long-term hospitalization. In order to optimize resource use, we recommend a close cooperation between hematology and hepatology teams [19] , as we previously suggested [20] .
In conclusion, severe hematological adverse events in patients treated with PIs and RBV are more frequent than expected, an observation suggesting either a possible class effect of PIs in the development of these toxicities or an interaction to the drug combination in susceptible patients. Given the lifethreatening character of these complications in some patients, we highly recommend to promptly discontinue RBV if blood cells significantly drop and to avoid it in cases with increased risk of development of hematological toxicity. In addition, close cooperation between hematologists and hepatologists is also advisable. 
